Ketamine-Assisted Psychotherapy (KAP) is an innovative treatment that combines intravenous ketamine with psychotherapy in a carefully monitored clinical setting. At Senz, this treatment is being evaluated in an open-label clinical trial for individuals with persistent depression who have not responded sufficiently to previous treatments. The combination of ketamine, psychological support, and integration sessions aims to promote emotional processing, psychological flexibility, and lasting therapeutic change.
Adults (18 years and older)
TRD
A MADRS score above the established clinical cut-off, indicating clinically significant depressive symptoms
Insufficient response to at least two adequate antidepressant treatment trials and one evidence-based psychotherapy, or failure to achieve adequate improvement following at least three consecutive treatment steps in accordance with the Dutch Multidisciplinary Guideline for Depression
Current substance use disorder or recent illicit drug use
Substance use disorder not in remission for at least 3 months
Inability to abstain from alcohol for 24 hours before and after treatment
Acute suicidality
Clients of Senz with TRD who are eligible for IV ketamine treatment (KAP)
Cohort
Prospective
Not listed
Beck Depression Inventory
depression self-report measure. Zero is equivalent to no depression and 64 indicates the highest score on depression.
Montgomery-Åsberg Depression Rating Scale
depression clinician report. Zero is equivalent to no depression and 60 indicates the highest score on depression.
Click on the lead sponsor to view all of their trials.
Senz
Lead sponsor
Radboud University Medical Center
Collaborator
